Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

The U.S. inked Technology Prosperity Deals (TPD) with Japan and South Korea with an eye toward spurring collaboration on AI, ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...